Association of immune checkpoint inhibitors with muscle mass and density in patients with melanoma
Patients treated with ICIs had a significantly higher decline in PMD as compared to patients not treated with ICIs, which was not affected by baseline eGFR.
Authors
- Steven K. Boyd (ORCID: https://orcid.org/0000-0002-2930-5997)
- Matthias Walle (ORCID: https://orcid.org/0000-0003-3250-8143)
- Thomas G. Salopek (ORCID: https://orcid.org/0000-0001-6990-8680)
- Susan Ziolkowski (ORCID: https://orcid.org/0000-0002-0785-598X)
- Jasmine Gill
- Bryn E. Matheson
- Carrie Ye
- John Walker
- Ates Fettahoglu
- Joshua F. Baker
Institutions
- University of Alberta (CA)
- Palo Alto University (US)
- Research Canada (CA)
- Alberta Bone and Joint Health Institute (CA)
- Philadelphia VA Medical Center (US)
- Arthritis Research Centre of Canada (CA)
- University of Pennsylvania (US)
- Stanford University (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-02-03
- DOI
- https://doi.org/10.1093/oncolo/oyag029
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00